Theiler's murine encephalomyelitis virus (TMEV) infection of the central nervous system (CNS) induces
Introduction
Although the etiology of multiple sclerosis (MS), 1 an immune-mediated demyelinating disease of the central nervous system (CNS) in humans, remains largely unknown, several lines of evidence suggest the potential for a virus as the initial causative agent (Kurtzke, 1993; Waksman, 1995) . Theiler's murine encephalomyelitis virus (TMEV) is a member of the Picornaviridae family that induces a chronic progressive demyelinating pathology that closely resembles MS in susceptible strains of mice following intracerebral inoculation. TMEV-induced demyelinating disease (TMEV-IDD) is characterized clinically by an abnormal waddling gait resulting from an ascending hind limb spastic paralysis, and histologically by the presence of perivascular in ammatory mononuclear in ltrates within the CNS that result in primary demyelination (Lipton and Dal Canto, 1979; Miller and Karpus, 1994) .
It is believed that the mechanisms involved in the development of demyelination involve both direct and bystander immune-mediated processes as evidenced by the presence of in ammatory CD4
C and CD8
C T cells and macrophages within the target organ (Lipton et al, 1984; Pope et al, 1996) , and to a lesser extent, direct viral damage of oligodendrocytes and microglia due to persistent viral infection (Rodriguez et al, 1983; Graves et al, 1986; Ohara et al, 1990) . However, the exact nature of these immune effector responses and their contribution to disease pathogenesis is still a matter of some controversy. There is considerable evidence from our own lab, as well as others, that indicates a critical role for CD4 C Th1 cells in mediating both the initial and chronic pathogenesis of TMEV-IDD in the susceptible SJL/J strain, as demonstrated by antibody depletion studies (Rodriguez et al, 1986a; Friedmann et al, 1987; Welsh et al, 1987) , the correlation of delayed-type hypersensitivity (DTH) responses with the severity of disease (Miller et al, 1997) , and the increasing amounts of CD4 C Th1-derived pro-in ammatory cytokines expressed in the CNS throughout disease progression (Begolka et al, 1998) . Despite these signi cant ndings, there also exist numerous lines of often contradictory evidence from similar studies conducted in resistant C57BL/6 mice with gene deletions to additionally support the role of CD8 C T cells, not only in viral clearance and protection but also in promoting the demyelinating process (Rodriguez et al, 1986a; Rodriguez and Sriram, 1988; Fiette et al, 1993; Pullen et al, 1993; Njenga et al, 1996; Murray et al, 1998) .
Therefore, in this study we sought to de nitively establish the effector role of CD8 C T cells in the highly susceptible SJL/J mouse, by utilizing mice which are de cient in the expression of¯2-microglobulin (¯2M), which fail to positively select any CD8 C T cells (Koller et al, 1990; Zijlstra et al, 1990 ) . Our results clearly indicate, in correlation with our previous data in this system, that CD8 C T cells fail to provide a signi cant and demonstrable effector contribution to either the initiation or progression of TMEV-IDD clinical pathology or demyelination. In addition, our data also convincingly demonstrates that the absence of CD8 C T cells leads to an accelerated and more severe disease phenotype, as measured clinically, histologically, and by several in vitro parameters, leading to the conclusion that the role of CD8 C T cells is primarily for protection and/or regulation in this system. These data are consistent with our ongoing model for the SJL/J mouse wherein persistent CNS infection with TMEV leads to the continual activation and clonal expansion of TMEV-speci c, and eventually neuroantigen-speci c, CD4
C Th1 effector cells capable of secreting proin ammatory cytokines and chemokines. These proin ammatory molecules in turn lead to the recruitment and eventual accumulation of activated macrophages/microglia within the CNS resulting in demyelination via a nonspeci c bystander response.
Results
Accelerated onset and increased clinical severity of TMEV-IDD in¯2M-de cient mice Wild-type SJL and¯2M-de cient mice were monitored for the development of clinical signs of demyelination following infection with TMEV (Figure 1 ). Although the incidence rate for developing TMEV-IDD was not statistically distinct between the two groups (93.1% vs 75.8%),¯2M-de cient mice developed a heightened disease phenotype as measured by several parameters.¯2M-de cient mice had an accelerated disease onset when compared to control mice (MDO D 29.89 vs 35.08; P D :038), and a rapidly progressing chronic disease that was dramatically increased in severity over controls from day 32 postinfection (p.i.) throughout the measured clinical course.
The increased disease severity in the¯2M-de cient mice was also evident from gross CNS histology at day 50 p.i. (Figure 2) , showing large numbers of perivascular and parenchymal in ammatory in ltrates, which appear to be comprised primarily of Figure 1 Comparison of clinical disease course between TMEVinfected¯2M-de cient SJL mice and wild-type SJL controls. TMEV-IDD was induced in all mice using the BeAn strain of virus and animals were graded for clinical signs as described in Materials and Methods. Results are expressed as mean clinical score of affected animals vs days p.i. from three pooled experiments. Disease scores at 32, 38, and 48 days p.i. are signi cantly increased in¯2M-de cient vs controls as measured by the Mann-Whitney test (*P < .006). Mean day of clinical onset (MDO) is also accelerated in¯2M-de cient mice (**P D :038). No signi cant difference is observed in the disease incidence rate between¯2M-de cient mice (22/29-75.9%) and the wild-type controls (27/29-93.1%) as measured by Â 2 using Fisher's exact test (P D :1443).
Figure 2
Spinal cord histology of TMEV-infected¯2M-de cient SJL and wild-type SJL control mice. Two mice from each group were sacri ced by perfusion on day 50 p.i., and 10 1-¹m-thick sections from the lumbar region of the spinal cord were stained with toluidine blue and examined by light microscopy for evidence of in ammatory in ltrate and demyelination. Pathologic changes were graded as follows: , no disease; C/ , meningeal in ammation; C, focal parenchymal in ammation with demyelination; CC, multiple areas of parenchymal in ammation and demyelination; CCC, extensive in ammation and demyelination with con uent lesions. Shown is representative section for each group of mice, with the wild-type SJL receiving an overall score of C, and the¯2M-de cient SJL receiving an overall score of CCC.
myelin debris-containing macrophages, as well as extensive white matter demyelination, compared to the milder perivascular CNS damage in wild-type controls. To address if there were qualitative and/or quantitative changes in the nature of the in ammatory in ltrate between the two groups, we also performed immunohistochemistry for CD4, CD8, and F4/80 in ltrates. The increased CNS in ltrates in thē 2M-de cient mice were largely the result of accumulation of F4/80 C macrophages/microglia, rather than CD4
C effector cells which were fairly equivalent between wild-type and¯2M-de cient mice (Figure 3) . As expected, staining for CD8 C T cells was detected in the wild-type infected CNS, albeit at low levels, yet completely absent in¯2M-de cient mice, con rming their phenotype. Isotype-matched controls for each antibody as well as staining of CNS tissue from naṏve mice revealed no positive cells for any of the three tested markers (data not shown).
Increased viral persistence in the CNS of TMEVinfected¯2M-de cient mice While the clinical and histological disease was exacerbated in the¯2M-de cient mice, it was also of interest to determine if the severe disease pathology could be attributed to alterations in viral clearance within the CNS due to the lack of cytolytic CD8 C T cells. Viral plaque assays of brain and spinal cord tissue from TMEV-infected 2M-de cient mice at day 50 p.i. revealed a 2-2.5-fold increase in viral titer from both the brain and spinal cord as compared to the wild-type control mice ( Figure 4A ). Overall, higher levels of virus were isolated from the spinal cord in both groups correlating with the previous observation that TMEV persists to a higher level in this CNS tissue at later time points in disease (Lipton et al, 1984) . As expected, homogenized kidney samples from both TMEV-infected groups failed to yield any detectable plaques (data not shown). Semiquantitative RT-PCR from spinal cord samples at this same time point also demonstrated an increase in mRNA levels for the TMEV capsid proteins VP1 and VP3 as seen in the plaque assays (Figure 4B) . This data illustrates the critical role of the CD8 C T cell in the highly susceptible SJL mouse in regulating levels of infectious virus, and not in contributing to the TMEV-IDD demyelinating pathology.
T cell responses to both TMEV and myelin epitopes are increased in¯2M-de cient mice The data to this point indicate that the clinical presentation of TMEV-IDD differs dramatically in the presence or absence of CD8 C T cells in the SJL host, and that in¯2M-de cient mice the exacerbated disease severity may be attributed to the pronounced in ammatory in ltrate and increased viral titer. We next sought to determine if the pattern of peripheral immune reactivity to TMEV and myelin proteins, as measured by both in vivo and in vitro assays was altered between thē 2M-de cient and control mice, and thereby provide additional evidence of a contributing mechanism for the observed accelerated disease. Delayed-type hypersensitivity (DTH) analysis of TMEV-infected¯2M-de cient at day 50 p.i. demonstrated no signi cant difference in the level of in vivo reactivity to either UV-inactivated TMEV, the immunodominant VP2 70-86 capsid protein peptide, or the immunodominant myelin epitope PLP139-151 when compared to the wild-type infected controls ( Figure 5 ). This does C and CD8 C T cells, and F4/80 C macrophages/microglia in the spinal cords of wild-type and¯2M-de cient SJL mice with TMEV-IDD. Spinal cord sections from mice from day 50 p.i. were stained for expression of CD4, CD8, and F4/80 as described in Materials and Methods. Shown is a representative section from each group of mice for each cell surface marker. In the top panels F4/80 staining is shown in red; in the middle panels, CD4 staining is shown in green with a blue DAPI counterstain; and, in the bottom panels, CD8 staining is shown in blue with red propidium iodide counterstain. Magni cation is 100£. Isotype-matched control antibody did not stain spinal cords from affected mice, nor was any positive staining revealed in the spinal cords of naṏve mice (data not shown).
Figure 4
Increased viral titers and mRNA for viral proteins are found in the brain and spinal cord of TMEV-infected¯2M-de cient SJL mice. In panel A, three mice at day 60 p.i. from each group were sacri ced, and brain, spinal cord, and kidney (not shown) were isolated, pooled, and processed for a viral plaque assay as described in Materials and Methods. Viral plaques in a BHK monolayer were counted over a series of four dilutions of tissue lysate, with the data shown as the mean PFU (plaque forming unit) per mg of brain and spinal cord starting tissue. Control kidney lysate did not yield any viral plaques. These results are representative of two separate experiments. In panel B, spinal cord-derived RNA from mice at day 60 p.i. was used as a template for semi-quantitative RT-PCR for the TMEV viral capsid proteins VP1 (495bp) and VP3 (445bp).
indicate, however, that¯2M-de cient mice are fully competent in developing and sustaining a CD4 C Th1-mediated response.
Although this observation is interesting, it is also possible that we may have missed an accelerated activation and expansion of PLP139-151-speci c T cells Figure 5¯2M -de cient mice display signi cant DTH responses to whole TMEV and myelin epitopes. DTH responses to TMEV, PLP139-151, and OVA323-339 were assessed at day 50 p.i. from TMEV-infected¯2M-de cient and wild-type control mice (n D 5). The results are expressed as the 24-h ear swelling in units of 10 4 inches § SEM in response to ear challenge with 5 ¹g UVinactivated TMEV, 10 ¹g PLP139-151, or 10 ¹g OVA323-339. These results are representative of two separate experiments. *DTH responses were signi cantly greater than uninfected controls as measured by the Student's t-test (P < .001).
at the day-50 time point, given that the majority of 2M-de cient mice have already progressed to a severe clinical disease, and may now be displaying enhanced reactivity to additional myelin epitopes not tested. We therefore performed DTH at an earlier time point in disease (day 35 p.i.), and despite yielding similar results for TMEV and VP2 70-86, the¯2M-de cient mice now displayed a trend (bordering on signi cance) toward increased responses to PLP139-151 compared to controls, indicative of accelerated epitope spreading (data not shown).
This trend toward increased neuroantigen reactivity was also observed in the in vitro splenic proliferative responses to both viral and myelin epitopes.¯2M-de cient mice demonstrated comparable to slightly higher responses, as measured by stimulation indexes, to intact TMEV and VP2 70-86 ( Figure 6A ), yet dramatically increased reactivity to PLP139-151 (SI D 10.1 vs 3.2) ( Figure 6B ). Responses to the irrelevant antigen OVA 323-339 were not detected in any experimental group. Given that we have previously demonstrated the ability to detect only low levels of proliferation to this immunodominant epitope at this time point from wild-type animals (Miller et al, 1997) , collectively these data additionally support the immunological phenomenon of epitope spreading as a contributing factor in the accelerated disease phenotype observed in the¯2M-de cient mice.
Increased levels of macrophage-derived proin ammatory mediators in the CNS of¯2M-de cient mice With evidence of increased cellular in ltrate, viral titer and cellular responses, we were also interested in the resulting cytokine pro le during TMEV-IDD within the CNS of infected animals, as we have previously demonstrated that the levels of mRNA for pro-and anti-in ammatory cytokines continue to increase throughout the disease course in the wild-type SJL mouse (Begolka et al, 1998) . Any increases in the levels of these cytokines in the¯2M-de cient mouse as compared to wild-type would also be indicative of, and contributing to, the observed accelerated disease. Total RNA isolated from mice at day 50 p.i. revealed similar results as the immunohistochemical analysis in Figure 3 , demonstrating a 2-fold increase in message for the F4/80 cell surface marker in¯2M-de cient mice, but not for CD4, and a concomitant increase in macrophage-derived proin ammatory cytokines such as TNF-®, IL-10, iNOS, and IL-12, without a corresponding increase in comparable cytokines produced by in ammatory CD4
C T cells, as measured by semiquantitative RT-PCR (Figure 7A-C) . A notable exception to this for the CD4 C population is the readily detectable increase in IL-4 mRNA, which may be increased as an attempt by the host at intrinsic regulation of a more severe disease pathology.
Discussion
A large body of research has attempted to ascertain whether CD4
C or CD8 C T cells are involved in the initiation, progression and/or regulation of TMEV-IDD. The evidence for CD4
C T cells as mediators of TMEV pathology in susceptible SJL mice is signicant in that: 1) monoclonal antibodies against CD4, MHC Class II, or IL-12 either prevented or diminished clinical signs (Friedmann et al, 1987; Welsh et al, 1987; Inoue et al, 1998) ; 2) ow cytometric and histological data from infected SJL/J mice revealed an increased level of CD4
C T cells and their proin ammatory cytokines during clinical disease progression, and transfer of a CD4
C VP2-speci c T cell line leads to increased incidence and accelerated onset of disease (Gerety et al, 1994; Pope et al, 1996; Begolka et al, 1998) ; 3) the development of virus and myelin antigen-speci c DTH corresponds with onset and chronicity of demyelination (Clatch et al, 1986; Miller et al, 1997) ; 4) epitopes of TMEV that elicit a Th1 response and DTH can accelerate the pathogenesis of TMEV upon active immunization (Yauch et al, 1998) ; and 5) tolerance via ECDI-coupled cells with TMEV, known to reduce IL-2 and IFN-°from Th1 cells, reduces the severity of disease (Peterson et al, 1993; Karpus et al, 1995) .
Although these data seem to rigorously support the role of CD4 C Th1 cells in both initiation and progression of TMEV-IDD, there are also a number of published reports suggesting the same is true for CD8 C T cells (Rodriguez et al, 1986a; Rodriguez and Sriram, 1988; Matloubian et al, 1994; Njenga et al, 1996; Murray et al, 1998) . However, as the majority of these studies were conducted using mice on a resistant genetic background (C57BL/6 and 129/J), in this study we sought to determine the outcome of the TMEV-IDD disease phenotype in the absence of CD8 C T cells in the highly susceptible SJL/J mice that were de cient in the expression of¯2M. Previous reports examining the effects of this mutation or the MHC class I knockout counterpart have provided evidence that the absence of CD8 C T cells on the resistant background leads to the establishment of chronic demyelination with or without clinical signs, extensive CNS in ltrate, and high viral titers, leading one to conclude that the primary role of these cells is in protection and regulation of disease (Fiette et al, 1993; Pullen et al, 1993; Rodriguez et al, 1993; RiveraQuinones et al, 1998; Lavi et al, 1999) . The current results support this central role for CD8 C T cells, with the secondary conclusion that CD4 C effector T cells are suf cient to mediate disease pathogenesis.
First,¯2M-de cient mice are highly susceptible to TMEV-IDD, as there was no difference in the incidence rate when comparing them to control mice; however, their progression of disease was remarkable when observing several severity parameters.¯2M-de cient mice displayed an accelerated onset of disease, as well as a more severe clinical progression as measured by mean clinical score over the duration of the time course observed. In addition, in one experiment where the mice were allowed to progress to beyond 55 days p.i., 5 out of 11¯2M-de cient mice progressed to a clinical score of 4, with several mice eventually succumbing to the disease by day 60, an observation rarely seen with the wildtype SJL mouse (data not shown). Second, the severe clinical disease in the¯2M-de cient mice also correlated with the presence of large numbers of inammatory in ltrates comprised mainly of activated macrophages/microglia in conjunction with extensive white matter demyelination as compared to the control mice. Expression of cytokine mRNA from the CNS of infected mice additionally con rms the increase in activated macrophage/microglia in ltrate as well as their secreted pro-in ammatory mediators known to promote the CD4 C Th1 environment. Third, 2M-de cient mice were effectively able to mount a speci c immune response to both virus and myelin epitopes that was at a minimum equivalent to, yet often exceeded, that of wild-type controls. Last,¯2M-de cient mice were signi cantly hampered in their ability to control viral persistence in both the brain and spinal cord. Impressively, the current data extend the prior work done with resistant animals to the susceptible SJL/J mouse and con rm the phenotype previously observed. This correlation between outcomes regardless of the genetic background lends strong support to the distinct roles of CD4 C and CD8 C T cells in the TMEV model. Although data indicating the pivotal role of CD4 C T cells in the pathogenesis of TMEV-IDD have been previously reported, an equally compelling body of work also demonstrates the critical role CD8
C T cells play in the control of disease susceptibility. It has been clearly shown that : 1) susceptibility/resistance to TMEV maps to Class I H-2D (Clatch et al, 1985; Rodriguez and David, 1985; Rodriguez et al, 1986b; Kappel et al, 1991) ; 2) monoclonal antibody depletion of CD8 C T cells leads to earlier onset and increased disease severity (LarssonSciard et al, 1997); 3) virus-speci c CTLs are found at a higher frequency in the CNS of resistant mice than susceptible mice, and in vivo IL-2 therapy can effectively boost CTL responses in susceptible strains and diminish viral persistence (Lindsley et al, 1991; Pena Rossi et al, 1991; Lin et al, 1995; Dethlefs et al, 1997) ; 4) perforin KO mice on the normally resistant C57BL/6 background are able to be persistently infected with TMEV (Pena-Rossi et al, 1998); and 5) in the BALB/c system, transfer of a CD8
C population from the spleen of TMEV-infected donors protects recipients from disease induction (Nicholson et al, 1996; Haynes et al, 2000) . Taken as a whole, our data in the susceptible SJL/J mouse supplement and are consistent with these previously documented observations and further support a critical role for CD8 C T cells in regulating disease susceptibility and severity.
Our results are, however, in direct contrast with data suggesting CD8 C T cells contribute to the disease pathology of TMEV-IDD (Rivera-Quinones et al, 1998; Rodriguez and Sriram, 1988) . There are several possible explanations for these observed differences. With regard to the absence of CD4 C T cells leading to an exacerbated disease, the ability to provide cognate B cell to help production of antibody to control the peripheral and CNS viremia is critically impaired (Borrow et al, 1993) . This is supported by the fact that the anti-TMEV humoral response in susceptible animals is unable to completely clear the virus but is capable of dramatically limiting the spread early in the infection (Lipton and Gonzalez-Scarano, 1978) . To that end, CD4-de cient animals die of an overwhelming virally mediated encephalitis within 25 days p.i. (Rodriguez and Sriram, 1988) . The depletion of CD4 C T cells in the chronic stages of TMEV-IDD has not been directly addressed in the literature to this point, however, given the compelling evidence for a pathologic role of myelin-speci c autoimmunity in chronic disease progression (Miller et al, 1997) , it is strongly believed that in ltrating CD4
C T cells contribute more signi cantly to disease progression than its regulation. Our lab has recently addressed this hypothesis through the use of tolerance to a panel of myelin autoepitopes at later time during chronic disease with the observed outcome of diminished clinical score and decreased demyelinating pathology (manuscript submitted). In addition, as it has been demonstrated that susceptible mice are capable of mounting virus-speci c CTL responses (Lindsley et al, 1991) , it is interesting to note that CD4 C T cells have been reported to be required to perpetuate longterm CTL reactivity when infections become persistent, as in the case of LCMV (Matloubian et al, 1994) .
The observation that the absence of CD8 C T cells leads to a less severe disease is more dif cult to reconcile with our data (Rivera-Quinones et al, 1998) . It is possible that differences related to the strain of virus used (DA vs BeAn) may be a contributing factor, as it has not been completely determined what type of CD8
C responses are elicited during active infection with each strain of virus. It is well documented in both human and mouse that naṏve CD8 C T cells are capable of differentiating into Tc1 or Tc2 populations, analogous to Th1 and Th2 cells, depending on the cytokine environment present during initial stimulation (Croft et al, 1994; Seder and Le Gros, 1995; Carter and Dutton, 1996) . Tc1 development is promoted by IL-18, IL-12, and IFN-°leading to more of a cytolytic response, whereas Tc2 development is promoted by IL-4 leading to a predominant regulatory response (Li et al, 1997) . It is possible, then, that in the resistant C57BL/6 strain, where virus is cleared rapidly, that the predominant response is Tc1 in nature. This idea is supported by data indicating that C57BL/6-perforin KO mice are able to be persistently infected with TMEV (Pena-Rossi et al, 1998) , and that the absence of CD8
C T cells leads to viral titers that are dramatically increased (Figure 4) (Fiette et al, 1993; Pullen et al, 1993; Rodriguez et al, 1993; Rivera-Quinones et al, 1998; Lavi et al, 1999) . This would be in contrast to the susceptible SJL/J strain where the predominant response may be Tc2 in nature, and/or minimally a weak Tc1, and the initial viremia is controlled, but not cleared. These mice, although capable of mounting a cytolytic response during active infection, must be dependent on additional mechanisms to support viral clearance, with the most likely candidate being antibody-dependent responses. This is supported by our observation that the majority of¯2M-de cient mice, while displaying an accelerated disease onset and severity of TMEV-IDD, do not succumb to the pathology until after 60 days p.i. Their rapid progression of disease is then most likely a combination of increased viral titer leading to enhanced immune inltrate and demyelination rather than a virally mediated encephalitis, indicative of a signi cant regulatory response that is now absent.
Collectively, the current data lend additional support to our model of TMEV-IDD in the susceptible SJL/J mouse wherein persistent CNS infection with TMEV leads to the continual activation and clonal expansion of TMEV-speci c, and eventually neuroantigen-speci c, CD4
C Th1 effector cells capable of secreting pro-in ammatory cytokines and chemokines. These pro-in ammatory molecules continue to promote an environment favoring Th1 activation, and in turn lead to the additional recruitment and eventual accumulation of activated macrophages/microglia within the CNS resulting in demyelination via a nonspeci c bystander response. The role of CD8 C T cells in this model appears to be a combination of both Tc1 cytolytic and Tc2 regulatory responses, but overall they do not appear to contribute signi cantly to either the demyelinating pathology or the onset of neurological de cit.
Materials and methods
Mice Female SJL/J mice, 6-7 weeks old, were purchased from Harlan Laboratories (Indianapolis, IN).
2M-de cient SJL/J mice were purchased from the Jackson Labs (Bar Harbor, ME). All mice were housed in the Northwestern animal care facility and maintained on standard laboratory chow and water ad libitum. Severely paralyzed mice were afforded easier access to food and water.
Peptides PLP139-151(HSLGKWLGHPDKF), OVA 323-339 (ISQAVHAAHAEINEAGR), and VP2 70-86 (WTTSQEAFSHIRIPLP) were purchased from the Peptides International (Louisville, KY). Amino acid composition was veri ed by laser desorption mass spectroscopy and purity (>98%) was assessed by HPLC.
Induction and clinical evaluation of TMEV-IDD Mice were anesthetized with methoxy urane (Mallinckrodt Veterinary, Mundelein, IL) and inoculated in the right cerebral hemisphere with (2.9 £ 10 6 ) plaque-forming units of TMEV, strain BeAn 8386, in 30 ¹l DMEM. Mice were examined in a singleblinded fashion 2-3 times per week for the development of chronic gait abnormalities and spastic paralysis indicative of demyelination, and assigned a clinical score of 0 to 6 as follows: 0 D asymptomatic, 1 D mild waddling gait, 2 D severe waddling gait, intact righting re ex, 3 D severe waddling gait, spastic hind limb paralysis, impaired righting re ex, 4 D severe waddling gait, spastic hind limb paralysis, impaired righting re ex, mild dehydration, and/or malnutrition, 5 D total hind limb paralysis, severe dehydration, and/or malnutrition, 6 D death. The data are plotted as the mean clinical score for animals from three pooled experiments.
In vitro T cell proliferation assays T cell proliferative responses were assessed by incorporation of [ 3 H]-thymidine. A total of 10 6 viable splenocytes recovered from TMEV infected mice at day 50 p.i. were cultured in triplicate in 96-well, at-bottom plates in 0.2 ml HL-1 media (Biowhittaker, Walkersville, MD) supplemented with 5% FBS (Sigma, St. Louis, MO), 2 mM glutamine, 100 ¹g/ml streptomycin, and 100 U/ml penicillin (Gibco BRL, Gaithersburg, MD). A range of VP2 70-86, PLP139-151, and OVA323-339 peptide antigen concentrations (0.1-100 ¹M nal), and 5 ¹g of UV-inactivated intact TMEV were tested. Plates were pulsed with 1 ¹Ci [ 3 H]-thymidine after 72 h of culture and harvested for scintillation counting on a Packard TopCount plate reader 24 h later. The results are expressed as mean CPM of antigen containing cultures.
Delayed-type hypersensitivity (DTH) DTH responses were quantitated using a standard 24-h earswelling assay. Prechallenge ear thickness was determined using a Mitutoyo model 7326 engineer's micrometer (Schlesinger Tools, Brooklyn, NY) . DTH responses were elicited by injected 10 ¹g of peptide (in 10 ¹l of PBS), or 5 ¹g of UV-inactivated TMEV into the dorsal surface of the ear using a 100-¹l Hamilton syringe tted with a 30-gauge needle. Twenty-four h after ear challenge, the increase in ear thickness over pre-challenge measurements was determined. Results are expressed in units of 10 4 in § SEM. Earswelling responses were the result of mononuclear cell in ltration and showed typical DTH kinetics (i.e., minimal swelling at 4 h, maximal swelling 24-48 h).
CNS histology At day 50 p.i., 2 mice from each group were anesthetized and sacri ced by perfusion through the left ventricle with 10 ml of PBS, followed by 100 ml of chilled 3% glutaraldehyde in PBS, pH 7.3. Spinal cords were dissected from the vertebral canal, sectioned at 1-mm intervals, postxed in 1% osmic acid for 1 h, and processed for Epon embedding. Ten 1-¹m-thick sections from each spinal cord were stained with toluidine blue and examined by light microscopy. Pathologic changes were graded in a blinded manner as follows: , no disease; C/ , meningeal in ammation; C, focal parenchymal in ammation with demyelination; CC, multiple areas of parenchymal in ammation and demyelination; CCC, extensive in ammation and demyelination with con uent lesions.
Immunohistochemistry for CD4, CD8, and F4/80 At day 50 p.i., 2 mice from each group were anesthetized and sacri ced by perfusion through the left ventricle with 30 ml of ice-cold PBS. Spinal cords were removed by dissection, and 2-3-mm spinal blocks were immediately frozen in OCT (Miles Laboratories, Elkhart IN) in liquid nitrogen. The blocks were stored at 80 ± C in plastic bags to prevent dehydration. Then, 5-6-¹m-thick sections from the lumbar region (approximately L2-L3) were cut on a Reichert-Jung Cryocut 1800 cryotome (Leica Instruments, Deer eld, IL), mounted on Superfrost Plus electrostatically charges slides (Fisher Scienti c, Hanover Park, IL), air dried, and stored at 80 ± C. Slides were stained using Tyramide Signal ampli cation (TSA) Direct Kit (NEN Life Science Products, Boston, MA) according to the manufacturer's instructions. Sections from each group were thawed, air-dried, xed in acetone at room temperature, and rehydrated in 1£ PBS. Nonspeci c staining was blocked using anti CD16/CD32 (Fc°R II/III-2.4G2, Pharmingen, San Diego, CA), and an avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA) in addition to the blocking reagent provided by the TSA kit. Slides were stained with the following biotin-conjugated antibodies: antimacrophage (F4/80) (Caltag, Burlingame, CA); anti-CD4 (H129.19), and anti-CD8a (53-6.7) (Pharmingen). Sections were counterstained with DAPI (Sigma) or propidium iodide (Molecular Probes, Eugene, OR), and then coverslipped with Vectashield mounting medium (Vector). Slides were then examined by epi uorescence using a chroma triple-band lter (Chroma Technology Corporation, Brattleboro, VT). Four serial sections from each sample per group were analyzed at 100£ and 400£ magni cation throughout the entire spinal cord section, which included gray and white matter, and dorsal, ventral, and lateral regions.
Plaque assay for viral titer At day 50 p.i., 3-4 mice per group were sacri ced by anesthesia. The brain, spinal cord, and kidney were removed and homogenized in PBS, and diluted in serum-free DMEM to obtain at least three serial dilutions for the assay. BHK-21 cells seeded 2 days prior in 60 £ 15-cm tissue culture plates, and grown to con uency, were washed 1£ with serum-free DMEM prior to the addition of homogenized tissue dilutions. Infection of the BHK cells is accomplished by incubation of the serial dilutions of homogenate with the cells at room temperature for 1 h with occasional swirling. A sterile 2% top agar solution is added in equal volume to 2£ DMEM supplemented with 2% FBS, 5 mM L-glutamine, 200 ¹g/ml penicillin, and 200 ¹g/ml streptomycin. After the 1-h incubation, the DMEM/agar mixture is added to the plate and the BHK cells are incubated at 34 ± C for 6 days in a humidi ed environment. Following the 6-day incubation, the agar layer is removed and the BHK cells are xed with methanol. The cells are then stained with a crystal violet solution (6 g crystal violet, 100 ml ethanol, and 400 ml H 2 O), and the plaques are visualized on each plate. The number of plaques counted on each plate are multiplied by the homogenate dilution and the amount of homogenate added to the plate to determine the plaque forming units (PFU) per ml. The weight of the original starting tissue (mg) per ml of homogenate is then used to calculate the PFU/mg.
Isolation of RNA At day 50 following induction of TMEV-IDD, two mice from each group were anesthetized and perfused through the left ventricle with 50 ml of PBS. Spinal cords were extruded by ushing the vertebral canal with PBS and then rinsed in PBS. Tissues were forced through a 100-mesh stainless steel screen to give a single cell suspension and pelleted by centrifugation at 1200 RPM for 5 min at 4 ± C. The pellets were vigorously resuspended in 16 ml of 4 M guanidinium isothiocyanate/50 mM Tris-Cl (pH 7.5)/25 mM EDTA (Gibco BRL); 1% 2-mercaptoethanol. Shearing of DNA was facilitated by forcing the resulting suspension repeatedly through a 23-gauge needle. Total RNA was isolated by highspeed gradient centrifugation (27,000 RPM) of 8 ml lysate through a 3-ml 5.7 M CsCl pad using a SW41 swinging bucket rotor for 20 h at 4 ± C. The resulting RNA pellet was resuspended to a nal concentration of 1 ¹g/¹l with diethylpyrocarbonate (DEPC)-treated water and stored in aliquots at 70 ± C. First strand cDNA synthesis and RT-PCR First strand cDNA was generated from 2 ¹g total RNA using Advantage-RT Kit (Clontech, Palo Alto, CA) using 20 pmole oligo-dT primer as per the manufacturer's provided protocol in a total volume of 20 ¹l. Following rst strand synthesis, each cDNA sample was brought to a nal volume of 100 ¹l with distilled water. Final PCR conditions included 50 mM KCl; 10 mM Tris-Cl (pH 8.3); 2.5-5.0 mM MgCl 2 (empirically determined for each primer pair); 2 mM dNTPs; 100 pmoles of each 5 0 and 3 0 gene-speci c primer; 1 U Taq polymerase (Qiagen, Chatsworth, CA) and 5-10 ¹l diluted cDNA. Cycling conditions were 94 ± C, 40 s; 60 ± C, 20 s; 72 ± C, 40 s, for a total of 30 cycles; linked to a nal 72 ± C extension program for 3 min and then to a nal 4 ± C soak program. PCR products were run on an ethidium-bromide-containing 2% agarose gel and illuminated using an ultraviolet light source, then photographed using Polaroid type 667 lm. Gel images were then scanned into Adobe Photoshop using an Epson 1200-C scanner and imported as TIFF les into Kodak 1D Digital Science for densitometry. The sum intensity and band area were determined for
